



Form PTO-1449
(Rev. 8-83)

U.S. Department of Commerce
Patent and Trademark Office

10 Serial No.
826,809

Group Art Unit
1646

Filing Date
4-17-04

1 of 2
Atty. Docket No.
MSB-7273-D

Applicant(s) Armen B. Shanafelt

INFORMATION DISCLOSURE CITATION

U.S. PATENT DOCUMENTS

*		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.							DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
													YES	NO
PM	M	0	2	6	7	7	9	5	05/18/88	EP	C07K	13/00		
PM	N	0	1	6	3	2	4	9	12/04/85	EP	C12N	15/00		X
PM	O	0	1	1	9	6	2	1	09/26/84	EP	C12N	15/00		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

PM	S	Zurawski S.M. and Zurawski G., Receptor antagonist and selective agonist derivatives of mouse interleukin-2, Embo.J., 11(11): 3905-3910 (1992)
	T	Zurawski et al., Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor, Embo.J., 12(13): 5113-5119 (1993)
	U	Thèze et al., Interleukin 2 and its receptors: recent advances and new immunological functions, Immunol. Today, 17(10): 481-486 (1996)
	V	Xu et al., Biological and receptor-binding activities of human interleukin-2 mutated at residues 20Asp, 125Cys or 127Ser, Eur.Cytokine Netw., 6(4): 237-244 (1995)
	W	Jacobson et al., Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity, Proc.Natl.Sci., 93: 10405-10410 (1996)
	X	Smith K. A., Lowest Dose Interleukin-2 Immunotherapy, Blood, 81(6): 1414-1423 (1993)
	Y	Kaplan et al., Rational Immunotherapy with Interleukin 2, Biotech., 10(2): 157-162 (1992)
	Z	Buchli et al., Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog, Arch.Biochem. Biophys., 307(2): 411-415 (1993)
	AA	Cellular and Molecular Immunology, Abbas et al., eds., 1997, W.B. Saunders Company, Chapter 12, Cytokines, pp. 250-267
	BB	Immunology, Roitt et al., eds., 1996, pp. 8.8-8.16, Fourth Edition, Mosby

EXAMINER

Prema Menz

DATE CONSIDERED

7/13/06

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP section 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449
(Rev. 8-83)U.S. Department of Commerce
Patent and Trademark Office

2 of 2

Serial No. 107 826,809	Group Art Unit 1646	Filing Date 4-17-04	Any. Docket No. MSB-7273-D
------------------------------	------------------------	------------------------	-------------------------------

INFORMATION DISCLOSURE CITATION

Applicant(s) Armen B. Shanafelt

U.S. PATENT DOCUMENTS

*		DOCUMENT NO.							DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
PM	A	5	6	9	6	2	3	4	12/09/97	Zurawski et al.	530	351	08/01/94
	B	5	2	2	9	1	0	9	07/20/93	Grimm et al.	424	85.2	04/14/92
	C	5	2	0	6	3	4	4	04/27/93	Katre et al.	530	351	01/11/88
	D	5	1	1	6	9	4	3	05/26/92	Kothes et al.	530	351	05/10/88
	E	4	9	5	9	3	1	4	09/25/90	Mark et al.	435	69.1	02/07/85
	F	4	8	5	3	3	3	2	08/01/89	Mark et al.	435	252.33	12/21/84
	G	4	5	8	8	5	8	5	05/13/86	Mark et al.	424	85	09/08/84
✓	H	4	5	1	8	5	8	4	05/21/85	Mark et al.	424	85	12/20/83

FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.							DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
													YES	NO
PM	I	9	7	4	1	2	3	2	11/06/97	WO	C12N	15/24		
	J	9	7	3	1	6	2	2	09/04/97	WO	A61K	9/06		
	K	9	6	0	6	8	6	0	03/07/96	WO	C07K	14/54		
✓	L	8	9	0	4	6	6	5	06/01/89	WO	A61K	37/02		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

PM	P	Zurawski, S.M. and Zurawski, G., Mouse interleukin-2 structure-function studies: substitutions in the first α -helix can specifically inactivate p70 receptor binding and mutations in the fifth α -helix can specifically inactivate p55 receptor binding, Embo.J., 8(9): 2583-2590 (1989)
	Q	Zurawski et al., Partial agonist/antagonist mouse interleukin-2 proteins indicate that a third component of the receptor complex functions in signal transduction, Embo.J., 9(12): 3899-3905 (1990).
✓	R	Zurawski, G., Analysing lymphokine-receptor interactions of IL-1 and IL-2 by recombinant-DNA technology, Trends Biotech., 9: 250-257 (1991)

EXAMINER

Prerna Munk

DATE CONSIDERED

7/13/06

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP section 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.